Crucell corporate brochure (PDF)

Our business – Research and development, technologies and products
Development stage Discovery/
Pre-clinical
Phase I Phase II Phase III Marketed Description
Marketed products:
Quinvaxem® Fully liquid vaccine for protection against five childhood diseases.
Hepavax-Gene® Recombinant hepatitis B vaccine.
Epaxal® Junior Low-dosage, aluminum-free hepatitis A vaccine (0.25ml).
MoRu-Viraten® Vaccine for protection against measles and rubella.
Epaxal® Aluminum-free hepatitis A vaccine.
Vivotif® Oral typhoid vaccine.
Dukoral® Only internationally licensed oral vaccine against cholera.
Inflexal® V
Vaccines in development:
Virosomal adjuvanted influenza vaccine.
Flavimun® Yellow fever vaccine.
Tuberculosis Recombinant AdVac®-based tuberculosis vaccine. 1
Malaria Recombinant AdVac®-based malaria vaccine. 2
Ebola and Marburg Recombinant AdVac®-based Ebola and Marburg vaccine. 2
HIV Recombinant AdVac®-based HIV vaccine. 3
Cell-based Influenza Seasonal influenza vaccine produced on PER.C6.®
Universal influenza Universal influenza vaccine produced on PER.C6.®
HPV Recombinant AdVac®-based HPV vaccine. 4
RSV Recombinant AdVac®-based RSV vaccine. 5
Human monoclonal antibodies in development:
Rabies antibody combination
Mix of two monoclonal antibodies for post-exposure
treatment of rabies. 6
Influenza antibodies
Hepatitis C antibody
combination
1 Partnered with Aeras.
2 Partnered with NIH/NIAID, GSK.
3 Partnered with Harvard.
4 Human papilloma virus (HPV), partnered with Johnson & Johnson.
5 Respiratory syncytial virus (RSV), partnered with Johnson & Johnson.
6 Partnered with sanofi pasteur.
Antibodies neutralizing a wide range of influenza subtypes,
including H5 and H1.
Neutralizing monoclonal antibody combination across all
genotypes tested.
11